Ocular Manifestations of Inflammatory Bowel Disease
Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Completed
CT.gov ID
NCT04771039
Collaborator
(none)
87
95.3
Study Details
Study Description
Brief Summary
Ocular damage is found in the 3rd rank of extra intestinal manifestations (MEI) Potentially serious functional complications (see uveitis and risk of blindness) requiring rapid management Rare uveitis in the literature (0.5% -3%), study on a large sample to assess their prevalence in patients with IBD at the Nancy CHRU and describe all the ocular manifestations that can be found.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
87 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Ocular Manifestations of Chronic Inflammatory Bowel Disease (IBD): Retrospective Study in the Hepato-gastroenterology Department of the Nancy CHRU
Actual Study Start Date
:
Jan 1, 2013
Actual Primary Completion Date
:
Dec 1, 2020
Actual Study Completion Date
:
Dec 12, 2020
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| patients with chronic inflammatory bowel disease who consulted in ophthalmology
|
Other: reason for consultation
search in medical files for reasons for ophthalmology consultation, functional signs, clinical signs, treatment, characteristics of IBD
|
Outcome Measures
Primary Outcome Measures
- frequency [baseline]
frequency of ocular manifestations in inflammatory bowel disease
Secondary Outcome Measures
- Number [baseline]
Number of uveitis, scleritis and episcleritis; prevalence calculation
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Adult patients followed at Nancy University Hospital for IBD and having consulted in the ophthalmology department
Exclusion Criteria:
-
Minor patients
-
patients without IBD
-
patients for whom there is no ophthalmology consultation
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Central Hospital, Nancy, France
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT04771039
Other Study ID Numbers:
- HRIPH
First Posted:
Feb 25, 2021
Last Update Posted:
Feb 25, 2021
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: